Summary of project PR001990
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001990. The data can be accessed directly via it's Project DOI: 10.21228/M8H14D This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR001990 |
| Project DOI: | doi: 10.21228/M8H14D |
| Project Title: | Multi-Omics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Topotecan |
| Project Summary: | Glioblastoma (GB) is the most common primary malignant brain tumor, representing approximately 57% of all gliomas and 48% of all primary malignant central nervous system (CNS) tumors. Despite the best standard therapies, glioblastoma survivors have a brief survival time, about 24 months on average. The treatment is troublesome because the cancer cells may not respond well to specific therapies as they grow within an extensive network of blood vessels. A multi-omics approach to provide information on biomolecules from multiple layers appears promising for systematically and holistically understanding complex biology. However, till now, only few studies have utilized omics analysis to investigate the impact of anticancer drugs on GBM. Our study aimed to evaluate the impacts of the anticancer medications (paclitaxel 5.3 μg/mL and topotecan 0.26 μM) solely and in pairwise combination on the metabolic and proteomic signatures of the U87 cell line while utilizing the accurate ultra-high-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) analytical technology. The studied cancer cells wear treated with DMSO (control group), paclitaxel 5.3 µM, topotecan 0.26 µM, and a combination of paclitaxel 5.3 µM and topotecan 0.26 µM. Using One-way ANOVA, we observed 14 significantly altered metabolites compared to those cells treated with DMSO. For combination treatment (paclitaxel and topotecan), 10 metabolites were significantly dysregulated. The sparse partial least squares-discriminant analysis (sPLS-DA) showed minimal overlapping, indicating a difference between the four groups. While for proteomics, a total of 79 proteins were significantly dysregulated among the groups. These findings can aid in identifying new biomarkers associated with the utilized drugs and creating a map for targeted therapy. EIF3F, GNB2L1, HINT2, and RPA3 were shown to be significantly upregulated in the combination group when compared to the control. Moreover, ribosome, apoptosis, HIF-1 signaling, arginine and proline, glutathione, purine metabolism, apelin signaling pathway, and glycolysis were significantly altered in the combination group |
| Institute: | Sharjah Institute for Medical Research |
| Last Name: | Facility |
| First Name: | Core |
| Address: | M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates |
| Email: | tims-tof@sharjah.ac.ae |
| Phone: | +971 6 5057656 |
Summary of all studies in project PR001990
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST003194 | Multi-Omics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Topotecan | Homo sapiens | Sharjah Institute for Medical Research | MS | 2024-11-01 | 1 | 16 | Uploaded data (6.2G)* |
